Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). (scientific article published on 07 March 2013)

Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines

Q83163378

Vaccine-derived polioviruses

Q83227504

Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004

Q94419425

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

Q107473800

Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child.

Q50624426

The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.

Q52589732

[Analysis of genetic characteristics of type II non-wild poliovirus in mainland China, 2010].

Q54313891

Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.

Q54701314

Vaccine-Associated Paralytic Poliomyelitis

Q56460798

Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome

Q59074734

Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines

Q64128669

Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota

Q64133330

Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman

Q64134026

The molecular biology of poliovaccines

Q67508248

Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus

Q68265001

Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases

Q68276895

The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk and Sabin vaccines

Q68556793

Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter

Q68713113

Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984

Q70167082

Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates

Q70461518

Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys

Q71071700

Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients

Q71272211

Poliovirus type 1 isolated from a vaccine-associated case of paralytic poliomyelitis in Brazil

Q71325177

Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus

Q71748573

Genomic characterization of type 1 Sabin-related polioviruses isolated in Brazil

Q71773996

The relation between acute persisting spinal paralysis and poliomyelitis vaccine--results of a ten-year enquiry. WHO Consultative Group

Q72112122

Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses

Q72220241

Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis

Q72229545

WHO Expert Committee on Biological Standardization. Thirty-third report

Q72716456

Progress towards global poliomyelitis eradication. The approaching extinction of wild poliovirus type 2

Q73054494

Surveillance for polio eradication in the People's Republic of China

Q73467463

Transmission of wild poliovirus type 2--apparent global interruption

Q73790960

Requirements for persistent immunity to poliomyelitis

Q74235244

VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION *

Q22255613

Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001

Q24559785

Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence

Q24647825

Circulating vaccine-derived polioviruses: current state of knowledge

Q24655387

Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range

Q24655520

Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993

Q24682487

A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future

Q28261403

Basic concepts in RNA virus evolution

Q28282367

Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population

Q29616266

Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication

Q30690384

A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005.

Q30840117

Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence

Q31034162

Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar

Q33310740

Estimating the extent of vaccine-derived poliovirus infection

Q33380220

Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses

Q33438422

Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient

Q33678253

Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative

Q33777224

Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Q33800863

Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model

Q33809550

Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees

Q33842178

Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event

Q33987017

Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture

Q33988170

Update on vaccine-derived polioviruses.

Q34000154

Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient

Q34045658

Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus

Q34118664

Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China.

Q34120449

Long-term circulation of vaccine-derived poliovirus that causes paralytic disease.

Q34341696

From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed

Q34349482

Bottleneck-mediated quasispecies restriction during spread of an RNA virus from inoculation site to brain

Q34481724

An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China.

Q34569805

Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007.

Q34583358

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

Q34632088

Reaching the last one per cent: progress and challenges in global polio eradication

Q34637291

Vaccination against polio should not be stopped

Q34707400

Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis

Q34743074

Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population

Q34743352

Reversion to neurovirulence of the live-attenuated Sabin type 3 oral pollovirus vaccine

Q35448656

Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine

Q35845137

Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus

Q35851911

Vaccine policy changes and epidemiology of poliomyelitis in the United States

Q35916018

Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease

Q35952794

Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b

Q36252186

Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome

Q36313509

Molecular mechanisms of poliovirus variation and evolution.

Q36433907

Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China

Q36474274

A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Q36650977

Identification of two determinants that attenuate vaccine-related type 2 poliovirus

Q36682266

Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2

Q36689199

Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype

Q36781751

Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine

Q36781818

Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature

Q36784097

Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.

Q36794212

Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine

Q36831862

Genetic analysis of the attenuation phenotype of poliovirus type 1.

Q36862121

Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine.

Q36937921

Retrospective Analysis of a Local Cessation of Vaccination against Poliomyelitis: a Possible Scenario for the Future

Q37060273

Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine

Q37333852

Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication

Q37476112

Long-term excretion of vaccine-derived poliovirus by a healthy child

Q37683100

Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary

Q37891602

Expert review on poliovirus immunity and transmission

Q38026922

Multiple Genetic Changes Can Occur in the Oral Poliovaccines upon Replication in Humans

Q38481851

Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012.

Q39197432

Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States

Q39422064

Natural genetic exchanges between vaccine and wild poliovirus strains in humans.

Q39612254

A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating

Q40065544

Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania

Q40188790

Some observations on poliomyelitis lameness surveys.

Q40241999

Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children

Q41416634

Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar

Q41444113

Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine

Q41457675

Recombinant vaccine-derived poliovirus in Madagascar

Q42575462

A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine

Q42808932

Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources

Q43467223

Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees

Q43576336

Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction.

Q44392775

Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis.

Q44401277

Circulating vaccine derived polio viruses and their impact on global polio eradication

Q44454709

Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee

Q44498244

The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland.

Q45110568

Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009.

Q45157670

The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity

Q45210913

Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient

Q45222453

Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains

Q45256410

Modeling population immunity to support efforts to end the transmission of live polioviruses

Q45326635

A STUDY OF SABIN TYPE 1 ORAL VACCINE VIRUS DURING FIVE HUMAN PASSAGES.

Q45713959

Possible protective effect of previous type 2 infection against paralytic poliomyelitis due to type 1 virus

Q45719602

Relation of poliomyelitis virus types to clinical disease and geographic distribution: a preliminary report

Q45720217

Genetic characterization of sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract

Q45878942

Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in china: current immunization strategy effectively prevented its sustained transmission.

Q48061908

Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary

Q48067337

Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications

Q48208472

The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut.

Q48324846

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

Q50183859

Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982.

Q50588231

Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.

Q50595907

P433

issue

P921

main subject

vaccine

polio vaccine

Poliovirus

page(s)

680-702

P577

publication date

2013-03-07

P1433

published in

Risk Analysis

Q7336230

P1476

title

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

P478

volume

Reverse relations

cites work (P2860)

Q38637663	Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future
Q35787304	An economic analysis of poliovirus risk management policy options for 2013-2052
Q41122240	Applying the Concept of Peptide Uniqueness to Anti-Polio Vaccination.
Q55114845	Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Q35968325	Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame
Q34632088	Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.
Q35662053	Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria
Q37542082	Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.
Q92052174	Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
Q38914168	Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped
Q64136837	Epidemiological serosurvey of poliovirus in Guangdong, China: A cross-sectional study
Q42262657	Genetic analysis of poliovirus strains isolated from sewage in Poland.
Q41468945	Good news for billions of children who will receive IPV.
Q35758622	Has Wild Poliovirus Been Eliminated from Nigeria?
Q35779660	Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
Q40238369	Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses
Q38323836	Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication
Q36035498	Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Q36031421	Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
Q38637670	Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective
Q42156511	Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.
Q40071746	Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
Q40071754	Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission
Q93082854	Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
Q33873406	Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation
Q30204646	Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
Q35787331	Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
Q47556747	Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations
Q57182247	Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan
Q41692843	Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.
Q53335042	Modeling poliovirus risks and the legacy of polio eradication.
Q39112948	Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India
Q42183582	Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
Q42183580	Modeling the dynamics of oral poliovirus vaccine cessation
Q42183578	Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Q35131980	Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
Q43373067	Modelling Risk to US Military Populations from Stopping Blanket Mandatory Polio Vaccination
Q38168905	National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.
Q55344705	Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Q58791913	Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
Q38322526	Polio endgame: the global introduction of inactivated polio vaccine
Q40838379	Polio endgame: the global switch from tOPV to bOPV.
Q39258694	Poliovirus vaccination during the endgame: insights from integrated modeling.
Q104288274	Poliovirus vaccine options: another step forward
Q38086593	Preeradication vaccine policy options for poliovirus infection and disease control.
Q36433974	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria
Q98210294	Sero-survey of polio antibodies and quality of acute flaccid paralysis surveillance in Chongqing, China: A cross-sectional study
Q38740160	The Evolutionary Pathway to Virulence of an RNA Virus
Q35779856	The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
Q38796753	The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management
Q37568832	The potential impact of expanding target age groups for polio immunization campaigns
Q41925239	The risk of type 2 oral polio vaccine use in post-cessation outbreak response
Q90918713	Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
Q38260375	Vaccine-derived polioviruses

P356	DOI	10.1111/RISA.12022
P698	PubMed publication ID	23470192